Halozyme Therapeutics (HALO) to Release Quarterly Earnings on Tuesday

Halozyme Therapeutics (NASDAQ:HALO) is anticipated to issue its quarterly earnings data after the market closes on Tuesday, February 18th. Analysts expect the company to announce earnings of $1.17 per share and revenue of $285.74 million for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $58.29 on Friday. Halozyme Therapeutics has a 12-month low of $35.23 and a 12-month high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The firm has a market capitalization of $7.42 billion, a P/E ratio of 19.30, a P/E/G ratio of 0.44 and a beta of 1.25. The firm’s fifty day simple moving average is $52.50 and its two-hundred day simple moving average is $54.49.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HALO. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, February 4th. Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. JMP Securities lifted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Finally, Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $60.89.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.